Test–retest reliability of the Friedreich’s ataxia rating scale
Abstract The modified Friedreich Ataxia Rating Scale (mFARS) is a disease specific, exam‐based neurological rating scale commonly used as a outcome measure in clinical trials. While extensive clinimetric testing indicates it’s validity in measuring disease progression, formal test–retest reliability...
Main Authors: | Christian Rummey, Theresa A. Zesiewicz, Santiago Perez‐Lloret, Jennifer M. Farmer, Massimo Pandolfo, David R. Lynch |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-09-01
|
Series: | Annals of Clinical and Translational Neurology |
Online Access: | https://doi.org/10.1002/acn3.51118 |
Similar Items
-
Predictors of loss of ambulation in Friedreich's ataxia
by: Christian Rummey, et al.
Published: (2020-01-01) -
Propensity matched comparison of omaveloxolone treatment to Friedreich ataxia natural history data
by: David R. Lynch, et al.
Published: (2024-01-01) -
Retinal hypoplasia and degeneration result in vision loss in Friedreich ataxia
by: Layne N. Rodden, et al.
Published: (2023-08-01) -
Cerebrospinal Fluid Proteomics in Friedreich Ataxia Reveals Markers of Neurodegeneration and Neuroinflammation
by: Virginie Imbault, et al.
Published: (2022-07-01) -
Clinical management guidelines for Friedreich ataxia: best practice in rare diseases
by: Louise A. Corben, et al.
Published: (2022-11-01)